# Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

> **NCT02029495** · PHASE3 · TERMINATED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 478 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** 210 mg brodalumab
- **DRUG:** 140 mg brodalumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02029495
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 478 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029495, "Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02029495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*